ANTIBIOTICS AS BIOLOGICAL RESPONSE MODIFIERS

被引:51
|
作者
RITTS, RE [1 ]
机构
[1] MAYO CLIN & MAYO FDN, MAYO GRAD SCH MED, RES MICROBIOL LAB, ROCHESTER, MN 55905 USA
关键词
D O I
10.1093/jac/26.suppl_C.31
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This review suggests that infections are potent immunomodulators by causing significant alterations in one or more mediators of homeostasis and that an effective antibiosis may be a potent immunomodulator, albeit indirectly. When large numbers of microorganisms are killed, their enzymes and toxins are rapidly released and activate the immune system. The septic syndrome and the potentially progressive states of septic shock, acute respiratory distress syndrome and multiple organ system failure illustrate the biological response modulating (BRM) activity of both infection and antibiotic. Enhancement of phagocytosis and intracellular killing would be a useful immunomodulatory activity for antibiotics. Equally useful would be the capacity of the antibiotic to bind or inactivate bacterial lipopolysaccharide (LPS) to diminish monocyte release of tumour-necrosing factor (TNF) at a rate equal to or faster than the killing effect of the antibiotic on bacteria. For other types of immune deficiencies, such as are observed in HIV-positive patients with secondary bacterial, fungal and viral infections, modulation of viral receptors including HFV-R on CD4 lymphocytes accompanied by their up-regulation, enhancement of interferon (IFN) and natural killer (NK) function and inhibition of CD8 suppressor activity would be important activities. The classic example of polymyxin as an immunomodulating, albeit toxic, antibiotic offers a rational and definitive basis for the concept In-vitro data on cefodizime, a third generation cephalosporin that achieves good tissue levels, are presented and show the ability of the intact antibiotic, as well as its immunomodulating side-chain, to down-regulate TNF and interleukin 1 (IL-1) released from human monocytes by lectin-activated lymphocytes, LPS and IFN. © 1990 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 50 条
  • [21] BIOLOGICAL RESPONSE MODIFIERS FOR THE THERAPY OF CANCER
    HERBERMAN, RB
    ANNALS OF ALLERGY, 1985, 54 (05): : 376 - 380
  • [22] BIOLOGICAL RESPONSE MODIFIERS - THE NEW IMMUNOTHERAPY
    FOON, KA
    CANCER RESEARCH, 1989, 49 (07) : 1621 - 1639
  • [23] Methods for evaluating biological response modifiers
    Harousseau, JL
    BULLETIN DU CANCER, 1998, 85 (12) : 993 - 996
  • [24] Biological response modifiers in rheumatoid arthritis
    Kassimos, D
    Mitton, D
    Whallett, A
    Delamere, JP
    Kitas, GD
    LANCET, 2002, 359 (9303): : 352 - 352
  • [25] EVALUATION OF BIOLOGICAL RESPONSE MODIFIERS INVITRO
    SALMON, SE
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1983, 2 (03): : 207 - 209
  • [26] NEW USES FOR BIOLOGICAL RESPONSE MODIFIERS
    MARWICK, C
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (10): : 1233 - 1233
  • [28] Biological Response Modifiers Used in Cancer Biotherapy
    Kuroki, Masahide
    Miyamoto, Shingo
    Morisaki, Takashi
    Yotsumoto, Fusanori
    Shirasu, Naoto
    Taniguchi, Yoshie
    Soma, Gen-Ichiro
    ANTICANCER RESEARCH, 2012, 32 (06) : 2229 - 2233
  • [29] THE USE OF BIOLOGICAL RESPONSE MODIFIERS IN PARASITIC INFECTIONS
    RUITENBERG, EJ
    BUYS, J
    BLOMJOUS, FJEM
    DEJONG, H
    BERNADINA, W
    DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, 1985, 62 : 129 - 138
  • [30] METABOLISM AND PHARMACOKINETICS OF BIOLOGICAL RESPONSE MODIFIERS (BRMS)
    BOCCI, V
    CARRARO, F
    NALDINI, A
    PAULESU, L
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (01) : 112 - 113